LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SC
Phase 1Recruiting 2 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 1
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Trial Timeline
May 16, 2025 → Dec 1, 2026
NCT ID
NCT06945406About LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SC
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SC is a phase 1 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 1. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06945406. Target conditions include Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 1 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06945406 | Phase 1 | Recruiting |
Competing Products
20 competing products in Diabetes Mellitus, Type 1